Investigational Drug Information for Solabegron
✉ Email this page to a colleague
What is the drug development status for Solabegron?
Solabegron is an investigational drug.
There have been 8 clinical trials for Solabegron.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 19th 2018.
The most common disease conditions in clinical trials are Urinary Bladder, Overactive, Irritable Bowel Syndrome, and Syndrome. The leading clinical trial sponsors are GlaxoSmithKline, Velicept Therapeutics, Inc., and [disabled in preview].
There are sixty-seven US patents protecting this investigational drug and one international patent.
Summary for Solabegron
| US Patents | 67 |
| International Patents | 1,103 |
| US Patent Applications | 285 |
| WIPO Patent Applications | 181 |
| Japanese Patent Applications | 86 |
| Clinical Trial Progress | Phase 2 (2018-02-19) |
| Vendors | 44 |
Recent Clinical Trials for Solabegron
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) | Velicept Therapeutics, Inc. | Phase 2 |
| Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women | Velicept Therapeutics, Inc. | Phase 2 |
| Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects | Velicept Therapeutics, Inc. | Phase 1 |
Clinical Trial Summary for Solabegron
Top disease conditions for Solabegron
Top clinical trial sponsors for Solabegron
US Patents for Solabegron
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Solabegron | ⤷ Try a Trial | Combination therapy | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | ⤷ Try a Trial |
| Solabegron | ⤷ Try a Trial | Treatment for diabetes in patients inappropriate for metformin therapy | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | ⤷ Try a Trial |
| Solabegron | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| Solabegron | ⤷ Try a Trial | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome | Boehringr Ingelheim International GmbH (Ingelheim am Rhein, DE) | ⤷ Try a Trial |
| Solabegron | ⤷ Try a Trial | Separation of proteins | Magtivio B.V. (CB Heerlen, NL) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Solabegron
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Solabegron | Austria | AT456369 | 2026-06-30 | ⤷ Try a Trial |
| Solabegron | Canada | CA2654798 | 2026-06-30 | ⤷ Try a Trial |
| Solabegron | Germany | DE602007004615 | 2026-06-30 | ⤷ Try a Trial |
| Solabegron | European Patent Office | EP2037927 | 2026-06-30 | ⤷ Try a Trial |
| Solabegron | Spain | ES2336719 | 2026-06-30 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
